Kidney International Reports最新文献

{"title":"Pilot Study of Using Machine Learning to Detect Atherosclerotic Renal Artery Stenosis From Spectral Doppler Waveforms","authors":"Haseeb Mukhtar ,&nbsp;Seyed Moein Rassoulinejad-Mousavi ,&nbsp;Shahriar Faghani ,&nbsp;Bradley J. Erickson ,&nbsp;Sanjay Misra","doi":"10.1016/j.ekir.2025.01.012","DOIUrl":"10.1016/j.ekir.2025.01.012","url":null,"abstract":"<div><h3>Introduction</h3><div>We investigated whether machine learning (ML) could be used to determine atherosclerotic renal artery stenosis (ARAS) using spectral Doppler waveforms in renal duplex ultrasound (DUS).</div></div><div><h3>Methods</h3><div>Patients with unilateral ARAS (contralateral normal kidney) confirmed by angiogram and requiring renal artery stent placement were retrospectively identified from January 2000 to January 2022. The exclusion criteria were unavailable preoperative renal DUS images, concomitant fibromuscular dysplasia, more than 1 renal artery on either side, or a previously placed renal artery stent with in-stent restenosis. Two hundred patients were selected; the affected kidney was used as the positive case and the contralateral kidney was used as the control. The spectral waveforms were reconstructed by manually tracing the outer envelope using WebPlot Digitizer. The graphical coordinates were then converted into 1-dimensional velocity signals. Signals were labeled as ARAS and normal and then randomly divided into training (80%) and testing (20%) datasets. A 1-dimensional convolutional neural network (CNN) was trained to classify the signals and detect ARAS. An Adam optimizer with a learning rate of 0.001 and a cross-entropy loss function were utilized. Five-fold cross-validation was applied, and the model was trained for 1000 epochs.</div></div><div><h3>Results</h3><div>A total of 396 signals were used from 198 patients after excluding 2 patients because of inadequate signal extraction (median age = 72 years, females = 51.0%). The overall accuracy of the trained model was 0.95 with a precision of 0.94. The area under the receiver operating characteristic curve was 0.97.</div></div><div><h3>Conclusion</h3><div>ML has been successfully employed to detect ARAS using arterial spectral Doppler waveforms in DUS.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1213-1222"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Timolol in the Treatment of Hemodialysis Tunneled Catheter Exit-Site Pyogenic Granuloma","authors":"Renato A. Caires ,&nbsp;Denise A.S. Braun ,&nbsp;William G. Arakaki ,&nbsp;Carlucci G. Ventura ,&nbsp;Fabio Di Nizo ,&nbsp;Jean Carlo R. Pegas ,&nbsp;Felicio L. Roque ,&nbsp;José Mauro Vieira Jr. ,&nbsp;Cláudio Luders","doi":"10.1016/j.ekir.2025.01.040","DOIUrl":"10.1016/j.ekir.2025.01.040","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1296-1299"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium Bicarbonate as an Alternative to Heparin for Catheter Lock in Hemodialysis","authors":"Rafaela Sierth ,&nbsp;Indianara Pires ,&nbsp;Rafael Marques da Silva ,&nbsp;Fabiana Baggio Nerbass","doi":"10.1016/j.ekir.2025.01.039","DOIUrl":"10.1016/j.ekir.2025.01.039","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Page 1300"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]","authors":"Hiddo J.L. Heerspink ,&nbsp;Meg Jardine ,&nbsp;Donald E. Kohan ,&nbsp;Richard A. Lafayette ,&nbsp;Adeera Levin ,&nbsp;Adrian Liew ,&nbsp;Hong Zhang ,&nbsp;Irene Noronha ,&nbsp;Hernan Trimarchi ,&nbsp;Fan Fan Hou ,&nbsp;Ronny Renfurm ,&nbsp;Todd Gray ,&nbsp;Marianne Camargo ,&nbsp;Jonathan Barratt","doi":"10.1016/j.ekir.2025.01.044","DOIUrl":"10.1016/j.ekir.2025.01.044","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Page 1302"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Patients","authors":"Jolijn R. van Leeuwen ,&nbsp;Obbo W. Bredewold ,&nbsp;Ton J. Rabelink ,&nbsp;Y.K.Onno Teng","doi":"10.1016/j.ekir.2025.01.022","DOIUrl":"10.1016/j.ekir.2025.01.022","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1288-1291"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Removal Notice to WCN24-1221 POSTERIOR ISCHEMIC OPTIC NEUROPATHY ASSOCIATED WITH HEMODIALYSIS IN A PATIENT WITH END-STAGE RENAL DISEASE [Kidney International Reports 9(4S) (2024) S384]","authors":"Jayson Villavicencio ∗ ,&nbsp;Darren Anthony Khow ,&nbsp;Bryan Vincent Mesina ,&nbsp;Janice Jill Lao","doi":"10.1016/j.ekir.2025.02.033","DOIUrl":"10.1016/j.ekir.2025.02.033","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Page 1303"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and Outcomes of Kidney Replacement Therapy Transitions in Canada","authors":"Louis-Charles Desbiens ,&nbsp;Karthik K. Tennankore ,&nbsp;Jeffrey Perl ,&nbsp;Christopher T. Chan ,&nbsp;Annie-Claire Nadeau-Fredette","doi":"10.1016/j.ekir.2025.01.008","DOIUrl":"10.1016/j.ekir.2025.01.008","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1279-1282"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes","authors":"Massini Merzkani ,&nbsp;Nyein Chann Wai Lynn ,&nbsp;Karen Flores ,&nbsp;Gaurav Rajashekar ,&nbsp;Kristin Progar ,&nbsp;Rowena Delos Santos ,&nbsp;John P. Atkinson ,&nbsp;Daniel C. Brennan ,&nbsp;Anuja Java","doi":"10.1016/j.ekir.2025.01.026","DOIUrl":"10.1016/j.ekir.2025.01.026","url":null,"abstract":"<div><h3>Introduction</h3><div>Thrombotic microangiopathy (TMA), characterized by small-vessel thrombosis caused by endothelial injury, presents significant diagnostic and treatment challenges in kidney transplantation.</div></div><div><h3>Methods</h3><div>To investigate the factors associated with posttransplant TMA, we conducted a retrospective study of 3535 kidney transplant recipients at our center from 2008 to 2023.</div></div><div><h3>Results</h3><div>Sixty-eight patients were diagnosed with TMA, and 93% (63 of 68) underwent genetic testing. Patients were categorized into 3 groups based on the TMA etiology. Group 1 (<em>n</em> = 42, 62%) included patients with complement-mediated TMA associated with genetic or acquired complement abnormalities. These patients were younger and had a higher incidence of hypertension (HTN) or preeclampsia as the causes of end-stage kidney disease (ESKD). Notably, 33% of patients developed recurrent TMA, and approximately 78% of those with recurrent TMA lost their allografts. Group 2 (<em>n</em> = 14, 21%) had TMA associated with calcineurin inhibitors (CNIs) or ischemia-reperfusion injury (IRI), showing longer cold ischemia times (CITs) (19.9 ± 8.7 hours vs. 10.7 ± 8.9 hours; <em>P</em> = 0.0001) and a higher rate of delayed graft function (DGF) (43% vs. 13%, <em>P</em> = 0.0008) than the controls. Group 3 (<em>n</em> = 12, 17%) had TMA from diverse causes (infections or autoimmune disorders) and exhibited a poor response to anticomplement therapy. No genetic variants were identified in this group.</div></div><div><h3>Conclusion</h3><div>Our findings underscore the need for comprehensive pre and posttransplantation genetic testing to predict and manage the risk of TMA and prevent graft loss. CNIs may exacerbate the risk of posttransplant TMA in the presence of other complement-activating factors. Our study also highlights the importance of personalized strategies and early interventions based on the functional assessment of variants of uncertain significance (VUS).</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1152-1162"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conservative Kidney Management in the Middle East and North Africa: Attitudes, Practices, and Implementation Barriers","authors":"Sahar H. Koubar ,&nbsp;Taha Hatab ,&nbsp;Farah Abdul Razzak ,&nbsp;Imed Helal ,&nbsp;Ala Ali ,&nbsp;Abdulhafid Shebani ,&nbsp;Saleh Kaysi ,&nbsp;David Gunderman ,&nbsp;Akram Al-Makki ,&nbsp;Sara N. Davison","doi":"10.1016/j.ekir.2025.01.011","DOIUrl":"10.1016/j.ekir.2025.01.011","url":null,"abstract":"<div><h3>Introduction</h3><div>Conservative kidney management (CKM) is poorly developed and not easily accessible globally, especially in middle- and low-income countries. This study aimed to understand the perspectives of nephrologists on CKM and the barriers to its implementation in the Middle East and North Africa (MENA) region.</div></div><div><h3>Methods</h3><div>We conducted an online survey. Nephrologists were contacted through their local nephrology societies. Responses were divided into the following 3 groups as per the country’s income classification by the World Bank: high-, middle-, and low-income.</div></div><div><h3>Results</h3><div>A total of 336 surveys were analyzed (response rate: 34.28%). The mean age of participants was 43.3 ± 9.8 years; 50% were male, 91% practiced in urban settings, and 18% were affiliated with academic centers. Of the participants, 76% were from middle-income countries. Nearly 80% of the participants were aware of CKM, and 65% accepted CKM as a treatment modality for kidney failure. However, only 20% consistently offered CKM to their patients and only 16% had a formal CKM program at their institution. Among these, 12% had a multidisciplinary team and only 6% had formal CKM training. The major perceived barriers to CKM implementation were financial and resource constraints (37.7% and 32.7%, respectively). Cultural and religious barriers constituted 18.3% and 8.6%, respectively, and were similar among the 3 income groups.</div></div><div><h3>Conclusion</h3><div>Despite the significant awareness of CKM in the MENA region, its implementation remains poor. Key barriers include financial limitations, resource shortages, and a lack of training. Regional and national research is required to address these challenges and guide policies to improve CKM accessibility and implementation.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1076-1086"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment","authors":"Qi Li ,&nbsp;Jin Shang ,&nbsp;Reiko Inagi","doi":"10.1016/j.ekir.2024.12.029","DOIUrl":"10.1016/j.ekir.2024.12.029","url":null,"abstract":"<div><div>Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD), affecting over 40% of patients with diabetes. DKD progression involves fibrosis and damage to glomerular and tubulointerstitial regions, with mitochondrial dysfunction playing a critical role. Impaired mitochondria lead to reduced adenosine triphosphate (ATP) production, damaged mitochondria accumulation, and increased reactive oxygen species (ROS), contributing to renal deterioration. Maintaining mitochondrial quality control (MQC) is essential for preventing cell death, tissue injury, and kidney failure. Recent clinical trials show that enhancing MQC can alleviate DKD. However, current treatments cannot halt kidney function decline, underscoring the need for new therapeutic strategies. Mitochondrial-targeted drugs show potential; however, challenges remain because of adverse effects and unclear mechanisms. Future research should aim to comprehensively explore therapeutic potential of MQC in DKD. This review highlights the significance of MQC in DKD treatment, emphasizing the need to maintain mitochondrial quality for developing new therapies.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 994-1010"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}